Articles On Neuren Pharmaceuticals (ASX:NEU)

The ASX finished 0.67% higher, marking the best performance by the Australian bourse since early October. Almost all sectors finished higher with energy and tech – two sectors under siege in recent weeks – recording gains of 2.07% and 1.9%...

The share market climbed for a third day, adding to gains after the Reserve Bank appeared to open the door to a rate rise next year. The S&P/ASX 200 sealed its longest winning run in more than a month with an advance of 69 points or...

Highlights Newly listed companyRocketBoots declined as much as 17.5% on ASX debut. Zip Co surged more than 9% on strong business growth in November. Neuren Pharma spiked over 100% on positive trial results for its drug Trofinetide....

Highlights The ASX 200 traded higher by 0.6% by mid-session on Tuesday. Barring utilities and materials, all sectors traded in the green zone. Travel stocks surged on easing concerns about the Omicron variant. Newly listed company Ro...

Neuren Pharmaceuticals’ (NEU) partner has announced positive top-line results from a phase three study on Rett syndrome Acadia Pharmaceuticals’ phase three “Lavender” study evaluated the efficacy and safety of investigational drug trofinet...

The share market climbed to its highest in a week before tempering gains ahead of this afternoon’s Reserve Bank policy update. The S&P/ASX 200 trimmed a 67-point opening rally to 48 points or 0.66 per cent at mid-session. Travel s...

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price is soaring to yearly highs on the back of positive phase three clinical trial results. Shares are currently swapping hands at $3.40 apiece, up exactly 100% from yesterday’s close. Let...

The ASX 200 Health Index (XHJ) is down by 0.80% at the time of writing, compared to the broader index which is down by 0.40%. The stock price of Neuren Pharmaceuticals (ASX:NEU) is up 100% this morning after the company announced its North...

Neuren Pharmaceuticals (ASX:NEU) has reported that its partner for trofinetide in North America, Acadia Pharmaceuticals, has announced positive top-line results from a Phase 3 study.

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 25 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Going into...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 25 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week At the time...

Neuren Pharmaceuticals (NEU) releases its September quarterly report, highlighting the progress with its upcoming clinical trials The phase three LAVENDER trial in people with Rett syndrome is progressing and top-line results are expected...

Neuren Pharmaceuticals (ASX:NEU) has announced it has received a Notice of Allowance from the US Patent and Trademark Office for a new patent that covers NNZ-2591 to treat autism.

Neuren Pharmaceuticals (NEU) receives a Notice of Allowance from the US Patent and Trademark Office for NNZ-2591 to treat autism The patent is titled “Bicyclic compounds and methods for their use in treating autism” and extends to July 20...

Neuren Pharmaceuticals (ASX:NEU) has raised $20 million through a placement of new shares to institutional and sophisticated investors at $2.05 per share.

ASX Capital Raise Roundup is a fortnightly look at ASX capital raisings. Investors were taken by surprise, in particular, with Thursday’s selloff. There were a number of explanations, but the biggest reasons resonating with us are seasonali...

Bankers for clinical-stage biotech company Neuren Pharmaceuticals will be pounding the virtual pavement on Friday morning.

Neuren Pharmaceuticals (ASX:NEU) has announced that the US FDA has granted Orphan Drug designation to its NNZ-2591 for the treatment of Prader-Willi syndrome.

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. Theme of the week The Healthcar...

Neuren Pharmaceuticals (ASX:NEU) today reported that its US partner for trofinetide, Acadia Pharmaceuticals, will be conducting a clinical trial in girls with diagnosed Rett syndrome.

Highlights  ASX-listed healthcare companies rarely fail to bring joy to the market participants, with a few of them providing outstanding returns in the last couple of months. Rhinomed, IDT Australia, and Prescient lead the way with ou...

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

Summary Emyria has signed a deal with the University of Western Australia (UWA) to develop a novel psychedelics pipeline. Pharmaxis’ anticancer drug PXS-5505 shows positive results in the pre-clinical liver cancer model. Immutep updat...

Summary Decmil (ASX:DCG) receives A$21 million civil balance of plant works contract dorsaVi (ASX:DVL) extends agreement with Medtronic Suvo (ASX:SUV) signs MOU and collaboration agreement with China-based Rezel The S&P/ASX2...

ASX 200 health stocks index (XHJ) rose by 0.23% this morning, compared to the broader index which rose by 0.11%. Micro cap medical device company dorsaVi (ASX:DVL) took the limelight this morning, jumping by 12% after saying that it has ext...

Neuren Pharmaceuticals (ASX: NEU) today announced that its US partner Acadia Pharmaceuticals has successfully completed enrolment in the LAVENDER Phase 3 trial of trofinetide in Rett syndrome.

Wall Street mixed on Fed’s statement US stock markets were mixed overnight, after the US Fed Vice Chair said he anticipates rates to increase by 2023. “Given this outlook and so long as inflation expectations remain well anchored at the 2%...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Healthcare...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. Theme of the week Healthcare fi...

Over the past month, a number of US FDA approvals have moved the share prices of global pharma stocks, including those traded here on the ASX. The biggest FDA announcement during the month came out of US-based Biogen, which received a contr...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week It has been...

Highlights: Clear and constructive guidance received from pre-IND meetings with the FDA Office of Neuroscience for Phase 2 clinical trials of NNZ-2591 in Phelan-McDermid, Angelman and Pitt Hopkins syndromes Positive outcome is an import...

The USA is the world’s largest healthcare market and therefore a dream for ASX health stocks to enter. This is no easy feat – needing to obtain the approval from the FDA, a regulator renowned as the world’s most sophisticated – but one that...

Neuren Pharmaceuticals (ASX:NEU) says it has received "clear and constructive guidance" from the US FDA Office of Neuroscience in pre-IND meetings for Phase 2 clinical trials of NNZ-2591.

Summary Neuren Pharmaceuticals obtained a Canadian patent grant for trofinetide, with a patent term that extends to January 2032. Health technology company Medibio Limited has secured a pre-submission meeting with the FDA for a new 510...

Neuren Pharmaceuticals (ASX:NEU) has announced that manufacturing of the drug substance for phase two trials of NNZ-2591 has been successfully completed on schedule.

Source:Master Video, Shutterstock Summary Neuren Pharmaceuticals updated the market that drug manufacturing for Phase 2 trials of NNZ-2591 has been completed. Cann Global’s Canntab Therapeutics has obtained an Australian patent with e...

Neuren Pharmaceuticals Ltd (ASX: NEU) shares are trending higher in early afternoon trade. This comes after the biotech company announced it has successfully completed manufacturing a drug substance for its Phase 2 trials. At the time of w...

What sounds more appealing for investors: a billion-dollar blockbuster drug with mass market appeal, or an ‘orphan’ drug targeting a ... Read More The post Dr Boreham’s Crucible: Is Neuren Pharmaceuticals’ Rett bet set for collect? appeared...

Australian biotechnology company Neuren Pharmaceuticals (ASX:NEU) has reported a phase one trial of its twice-daily oral investigative therapy NNZ-2591 found it was safe and well-tolerated for seven days.

Invex Therapeutics (ASX: IXC) is aiming to hit some significant milestones in 2021 in its bid to use a diabetic drug for a neurological condition in desperate need for treatment. The biopharmaceutical company is focused on repurposing the d...

The company is developing new therapies to treat serious neurological disorders that emerge in early childhood, none of which have any approved medicines, and is advancing development of its second drug candidate NNZ-2591 for Phelan-McDermi...

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price has changed direction today despite positive news on its drug trials.  In early morning trade, the biopharma company’s shares were up 2.7% to $1.50. But the Neuren share price has since...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

Melbourne-based company Neuren Pharmaceuticals (ASX:NEU) says it has initiated the manufacture of NNZ-2591 to supply the planned phase two clinical trials.

The sudden drop in spot gold prices and reintroduction of COVID-19 restrictions in New Zealand have hit the relevant ASX small caps this morning. After 100 days of being virus-free, four COVID-19 cases were detected in the country. New Zeal...

ASX companies continued to raise money in July, with over $4bn shelled out by investors, taking 2020’s total above $30bn. According to Bloomberg, there has been $32.3bn worth of cash raised between January 1 and August 3. This is well ahead...

Cancer therapeutics biotech Immutep (ASX:IMM) has enrolled and dosed the last patient for a segment of its phase 2 study into cancer treatments. The recruitment and dosing milestone was for stage 2 of Part A of its TACTI-002 phase II study....